These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20019269)

  • 21. B-RAF: A contributor to the melanoma phenotype.
    Heath EM; Kaufman KL; Christopherson RI
    Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective inhibitors of the mutant B-Raf pathway: discovery of a potent and orally bioavailable aminoisoquinoline.
    Smith AL; DeMorin FF; Paras NA; Huang Q; Petkus JK; Doherty EM; Nixey T; Kim JL; Whittington DA; Epstein LF; Lee MR; Rose MJ; Babij C; Fernando M; Hess K; Le Q; Beltran P; Carnahan J
    J Med Chem; 2009 Oct; 52(20):6189-92. PubMed ID: 19764794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant BRAF melanomas--dependence and resistance.
    Poulikakos PI; Rosen N
    Cancer Cell; 2011 Jan; 19(1):11-5. PubMed ID: 21251612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
    Schadendorf D
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
    [No Abstract]   [Full Text] [Related]  

  • 25. Advances in drug development. BRAF validation in melanoma.
    Flaherty K
    Clin Adv Hematol Oncol; 2010 Jan; 8(1):31-4. PubMed ID: 20351680
    [No Abstract]   [Full Text] [Related]  

  • 26. A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.
    Khan MA; El-Gamal MI; Oh CH
    Mini Rev Med Chem; 2017; 17(4):351-365. PubMed ID: 27337967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.
    Haluska F; Pemberton T; Ibrahim N; Kalinsky K
    Semin Oncol; 2007 Dec; 34(6):546-54. PubMed ID: 18083378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 29. Melanoma drug wins US approval.
    Ledford H
    Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150
    [No Abstract]   [Full Text] [Related]  

  • 30. [Gene abnormalities in melanoma and signal transduction antagonists].
    Takada M
    Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel inhibitors in the treatment of metastatic melanoma.
    Kalinsky K; Haluska FG
    Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting activated KIT signaling for melanoma therapy.
    Bastian BC; Esteve-Puig R
    J Clin Oncol; 2013 Sep; 31(26):3288-90. PubMed ID: 23940224
    [No Abstract]   [Full Text] [Related]  

  • 34. Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.
    Smalley KS; Aplin AE; Flaherty KT; Hoeller C; Bosserhoff AK; Haass NK; Bosenberg M; Ribas A; Barnhill R; Kudchadkar R; Messina JL
    Pigment Cell Melanoma Res; 2012 Jan; 25(1):E1-11. PubMed ID: 22117673
    [No Abstract]   [Full Text] [Related]  

  • 35. [Signal transduction in melanoma].
    Yokoyama S
    Seikagaku; 2013 Jun; 85(6):469-74. PubMed ID: 23875475
    [No Abstract]   [Full Text] [Related]  

  • 36. Fisetin: a natural fist against melanoma?
    Arbiser JL; Fisher DE
    J Invest Dermatol; 2011 Jun; 131(6):1187-9. PubMed ID: 21566577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Towards the targeted therapy of melanoma.
    Smalley KS; Herlyn M
    Mini Rev Med Chem; 2006 Apr; 6(4):387-93. PubMed ID: 16613575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular drivers of cellular metabolic reprogramming in melanoma.
    Abildgaard C; Guldberg P
    Trends Mol Med; 2015 Mar; 21(3):164-71. PubMed ID: 25618774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Notch for noncoding RNA in melanoma.
    Garraway LA
    N Engl J Med; 2014 May; 370(20):1950-1. PubMed ID: 24827041
    [No Abstract]   [Full Text] [Related]  

  • 40. Rare victory in fight against melanoma.
    Ledford H
    Nature; 2010 Sep; 467(7312):140-1. PubMed ID: 20829766
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.